Mylan Begins Marketing First Generic Version of Desoxyn(R)

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has begun to market Methamphetamine Hydrochloride Tablets USP, 5 mg, based on an agreement with licensing partner Coastal Pharmaceuticals. This product, used for the treatment of attention deficit hyperactivity disorder or obesity, is the first generic version of Lundbeck's Desoxyn to be approved by the FDA.

Methamphetamine Hydrochloride Tablets had U.S. sales of approximately $9.3 million for the 12 months ending Dec. 31, 2009, according to IMS Health.